Abstract We previously demonstrated the role of Kvb1.1 subunit of voltage-activated potassium channel in heart for its sensory roles in detecting changes in NADH/NAD and modulation of ion channel. However, the pharmacological role for the association of Kvb1 via its binding to ligands such as cortisone and its analogs remains unknown. Therefore, we investigated the significance of Kvb1.1 binding to cortisone analogs and AR inhibitor epalrestat. In addition, the aldose reductase (AR) inhibitor epalrestat was identified as a pharmacological target and modulator of cardiac activity via binding to the Kvb1 subunit. Using a combination of ex vivo cardiac electrophysiology and in silico binding, we identified that Kvb1 subunit binds and interacts with epalrestat. To identify the specificity of the action potential changes, we studied the sensitivity of the action potential prolongation by probing the electrical changes in the presence of 4-aminopyridine and evaluated the specificity of pharmacological effects in the hearts from Kvb1.1 knock out mouse. Our results show that pharmacological modulation of cardiac electrical activity by cortisone analogs and epalrestat is mediated by Kvb1.1.
Introduction
Glucocorticoids are utilized to manage autoimmune diseases and aid in controlling inflammation. However, glucocorticoids present with many cardiac effects including both beneficial as well as deleterious effects. Narayanan et al. demonstrated that a low-dose treatment with dexamethasone improved contractile performance [1] . Furthermore, pre-treatment with methylprednisolone resulted in significant protection against ischemia-reperfusion damage [2] . Chronic use of glucocorticoids, however, has demonstrated adverse effects including hypertension and heart failure. In adult rats, dexamethasone given for 15 days resulted in left ventricular hypertrophy and increased systolic pressure [3] . While much of the previous work was focused on understanding the mechanism for glucocorticoid via the activation of glucocorticoid and mineralocorticoid receptors, many questions remain in regard to factors that mediate the electrical effects of corticosteroids in the heart.
Previous research has demonstrated that glucocorticoids including cortisone, cortisone-21-acetate, and fluticasone bind Kvb subunit and dissociate the Kvb1.1 subunits from the Kv channel (Kv1.x), thus removing the Kvb subunitmediated Kv channel inactivation [4, 5] . The Kvb subunits represent a unique class of aldo-keto reductases (AKR) which bind and alter many different voltage-gated potassium channels (Kv) [6, 7] . Recently, we demonstrated that global knockout of Kvb1.1 in mouse resulted in significant prolongation of monophasic action potential as well at QTc [8] . Further, we also demonstrated that the binding of pyridine nucleotide to Kvb1.1 subunits can modulate the gating potential of Kv4.2 a key player in the I to current responsible for the initial phase of the repolarization in cardiac action potentials. The addition of lactate resulted in significant increase in intracellular NADH and led to increased rates of Kv4.2 inactivation cardiac action potential prolongation [7] . Therefore, we hypothesized that Kvb1.1 can interact with cortisone and other ligands and regulate the cardiac action potential.
While cortisone demonstrated two binding sites for the Kvb subunit, it is the interface site or the b-b interaction and the T1 domain of the Kv channel which induces dissociation and alters Kvb inactivation [4] . Cortisone analogs were shown previously to interact and dissociate the Kvb subunits from Kv channel by binding to same sites [5] . This dissociation leads to abolished inactivation of Kv1.x channels in heterologous system; however, the physiological consequences of cortisone and Kvb1.1 dissociation remain unknown. Therefore, we tested the physiological role of cortisone and fluticasone on ex vivo Langendorff perfused hearts from control and Kvb1.1 knockout hearts.
Kvb subunits belong to the aldo-keto reductase family and share common mechanisms and ancestral origins [9, 10] . Moreover, the aldose reductase (AR) inhibitor epalrestat is utilized for diabetic neuropathy [11] . Previous research has demonstrated that AR inhibitors have profound cardiac effects preserving cardiac contractility after ischemia-reperfusion injury in diabetic and non-diabetic hearts [12, 13] . Clinically, treatment with aldose reductase for over a year in diabetic patients with neuropathy improved contractile function [14] . Therefore, in the present study, we investigated the role of Kvb1.1 in modulating the cardiac action potential via its interactions with cortisone analogs and AR inhibitor epalrestat.
Materials and methods

Animals
Mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA); Kvb1.1 KO (global knockout) and control or WT mice (C57BL/6NJ) [7] . Mice 14-16 weeks of age (Males) were provided water and food ad libitum. All animal work was approved in advance by the Institutional Animal Care and Use Committee at the University of South Florida (Tampa, FL, USA).
Monophasic action potentials
Monophasic action potentials (MAPs) were recorded from ex vivo heart preparations as reported before [7, 15] . Briefly, 1 mg heparin (180 USP, Sigma-Aldrich, St. Louis, MO, USA) was injected into the mice following euthanizing with Somnasol (Pentobarbital Sodium, 50 mg (kg body weight), Henry Schein Animal Health, Dublin, OH, USA) by i.p. injection. A bilateral thoracotomy was performed to remove the hearts which were then retrogradely perfused with Krebs-Hanseleit buffer (mM-NaCl 119, NaHCO 3 25, KCl 4, KH 2 PO4 1.2, MgCl 2 1, CaCl 2 1.8, Dglucose 10 and Sodium pyruvate 2, pH 7.4) at a constant flow rate of 2.0 ml/min and temperature of 37°C. MAP recordings were obtained from the left ventricular (LV) epicardial surface using a contact electrode (Harvard Apparatus, Holliston, MA, USA). MAP data were obtained after 10-min stabilization and acquired using 8-channel PowerLab system (AD Instruments, UK).
WT and KO MAPs were obtained to assess the activity in response to cortisone, fluticasone, epalrestat, and 4-aminopyridine (4-AP). Baseline MAPs from the LV were obtained with Krebs-Hanseleit buffer; subsequently, hearts were then perfused for 20 min with a cortisone (500 lM), fluticasone (100 nM), epalrestat (100 lM), and a combination of cortisone (500 lM) and 4-AP (2 mM) (8). MAPs were recorded using 8-channel PowerLab system (AD Instruments, UK).
Docking study
In silico analysis for binding of human Kvb2 (PDB: 1ZSX) to epalrestat ligand (Pubchem-CID 1549120) was performed by using Discovery Studio software. The crystal structure of Kvb2 co-crystalizes with NADP ? at the active site which was utilized for ligand docking study.
Statistical analysis
Statistical analyses were performed with Sigma Plot (v.11.0). When comparing two groups, an independent Student's t test was used. Data are expressed as mean ± SEM; and p B 0.05 were considered significant.
Results
Cortisone exposure significantly prolongs cardiac action potentials Cortisone (500 lM) exposure to ex vivo perfused WT hearts led to a significant increase in action potential durations at 20, 50, and 70% repolarization (Fig. 1) . However, similar exposure of cortisone to Kvb1.1 KO hearts demonstrated no significant alternations in action potential durations when compared with baseline measurements or those prior to cortisone exposure (Fig. 1c) . Similar to previously published research, KO hearts demonstrated a significant increase in APDs at 20, 50, and 70% when compared with WT hearts at baseline.
Fluticasone exposure significantly alters cardiac action potentials
Acute exposure with fluticasone (100 nM), which is a widely used steroid in respiratory illnesses, to WT hearts led to a significant prolongation in action potential durations at 20, 50, and 70% repolarization (Fig. 2) . However, fluticasone resulted in no significant prolongation in KO hearts. Similar baseline values were obtained between WT and KO demonstrating significant prolongation in KO compared with WT hearts.
AR inhibitor Epalrestat exposure prolongs cardiac action potentials
Epalrestat is an aldose reductase inhibitor; however, its cardiovascular effects in Kvb1.1 KO mice remain unknown. Acute exposure to epalrestat in WT hearts led to significant action potential prolongation at 20, 50, and 70% repolarization. Interestingly, KO hearts showed no significant increase in action potential durations as compared with baseline measurements (Fig. 3 ).
Cortisone along with 4-aminopyridine significantly prolongs the cardiac action potential
To dissect the 4-AP-sensitive portion of the cardiac action potential, we utilized 2 mM 4-amino pyridine to identify the cortisone effects and distinguish the 4-AP-mediated effects. 4-AP exposure alone in WT or KO ex vivo hearts demonstrated significant prolongation of action potential durations at 20, 50, and 70% repolarization (Fig. 4) .
WT hearts perfused with cortisone showed significant action potential prolongation at APD 50 and APD 70; however, the KO hearts failed to prolong the APD. However, a combination of cortisone ? 4-AP (500 lM and 2 mM) demonstrated APD prolongation in both WT and KO hearts suggesting that 4-AP mediates the APD prolongation independent of Kvb1.1 subunit (Fig. 5) [16] .
Epalrestat demonstrates binding interaction with the Kvb subunits
As shown in Fig. 6a , the comparative alignment of sequences for human Kvb2, rat Kvb2, and mouse Kvb1 shows conserved amino acid residues such as the cysteine (C234 human, 248 rat, and 282 mouse), following this, six amino acids after is noticed by lysine (240 human, 254 rat, 288 mouse) and tyrosine (241 human, 255 rat, and 289 mouse) and ten amino acids after that is an arginine (250 human, 264 rat, and 297 mouse) (Fig. 6a) . The binding pocket created by the key amino acids has been previously demonstrated as an important pyridine nucleotide binding site in which the mutation of rat 264R prevents the NADPH molecule from binding with the Kvb subunit [17, 18] . Novel in silico docking in this study identifies that epalrestat interacts with the arginine forming a hydrogen bond, thus preventing the necessary interaction between NADPH (shown overlaid in line format) and the Kvb's arginine residue (Fig. 6b) . Further amino acid inspection of Kvb subunit and epalrestat demonstrates within this binding pocket the C5 and lysine 240 interact at a distance of 1.8 and an angle of / = 127.074, h = 157.152, and energy 2.438 (Fig. 6c) . Epalrestat demonstrates novel in silico interactions here while also demonstrating profound physiological alterations within the ex vivo perfused heart in WT and in KO hearts.
Discussion
We identified major pharmacological role for Kvb1 in the heart based on the modulation of cardiac electrical activity by cortisone, its analogs, and epalrestat (aldose reductase inhibitor). We report in silico binding of aldose reductase inhibitor epalrestat to Kvb1 subunit which allows for action potential prolongation at APD 20, 50, and 70. Therefore, Kvb1.1 subunit offers a potential target for therapeutic interventions of cardiac arrhythmia.
Previous report by Pan et al. shows that Kvb subunits demonstrate tight binding based on the X-ray crystallography studies combined with heterologous electrophysiology studies [5] . The regions responsible for cortisone binding are primarily at two locations of the Kvb subunit including one at the active site and the other at the interface between the domains (residues 75 and 76) where Kvb interacts with Kv channel. In the present study, we hypothesized that cortisone binding to Kvb subunits plays a significant pharmacological role in the heart. Our investigation reveals that indeed cortisone allows the electrophysiological modulation at the action potential level by prolonging the action potential duration. We repolarization showing significant increases after fluticasone treatment in WT while having no effect in Kvb1.1 KO hearts. The data represent mean ± SEM (n = 5 hearts) *p \ 0.05. c APD at 50%
repolarization showing significant increase after fluticasone treatment in WT but no effect in KO hearts. The data represent mean ± SEM (n = 5 hearts) *p \ 0.05. d APD at 70% repolarization showing increases after fluticasone treatment in WT but no effect in Kvb1.1 KO hearts. The data represent mean ± SEM (n = 5 hearts) *p \ 0.05. (Color figure online) identified that cortisone has the highest propensity for APD prolongation followed by fluticasone. In addition to cortisone, we investigated the aldose reductase inhibitor epalrestat for its pharmacological role in modulating cardiac activity [19] . Based on our data, it is clear that epalrestat prolongs the APD in the wildtype hearts, whereas the Kvb1 knockout mouse heart failed to prolong the APD, demonstrating that Kvb1 has a role in mediating the pharmacological activity.
At physiological level, since the cortisone and its analogs bind Kvb1 subunit, it allows for a direct Kvb1-Kv channel interaction that can be altered due to the affinity for cortisone. As noted in previous report [4, 5] , it is likely that cortisone dissociates the assembly of Kvb1-Kv interaction leading to a decreased Kv channel prowess causing prolongation of APD. Since the Kvb1 subunit is knocked out in the Kvb1.1 KO mouse heart, it is plausible that the effects of cortisone were abolished and the APD remained unaltered due to appearance of cortisone or fluticasone.
To identify the specificity of cortisone-mediated action potential changes, we utilized 4-amino pyridine which selectively alters Kv channel-mediated responses. Based on the combined effects demonstrated by cortisone and 4-aminopyridine, we identified that cortisone mediates the action potential prolongation via its ability to bind Kvb1.1 subunit, whereas 4-aminopyridine-mediated changes are due to its direct effects on the Kv channel. Therefore, our results suggest that the cortisone-mediated alteration in action potential is different than the 4-aminopyridine-sensitive action potential.
Cortisone is a stress hormone which increases under physiological stress [20] . However, the precise effect of cortisone on heart and electrical modulation remain unclear. To identify the effects of starvation on heart function and its relation to cortisone levels, another study identified the effects and revealed that prolonged starvation leads to stressrelated cortisone levels and impacts cardiac output and morphology in rats [21] . The present study clearly demonstrates that cortisone and its analogs can directly bind to Kvb1 and modulate the cardiac action potential, revealing the potential of such interactions for their utility as a pharmacological targets under metabolic stress.
Aldose reductase inhibitor epalrestat has been previously studied for assessing diabetic neuropathy in patients [19] . The use of epalrestat delays the progression of diabetic neuropathy by reducing sorbitol accumulation in different tissues such as sciatic nerves, ocular nerves, and erythrocytes. The anti-ischemic activity of epalrestat was reported by Calderone et al. identifying the role for AR inhibitors in diabetic ischemia-reperfusion injury [12] . However, the electrical modulation caused by the pharmacological inhibitor remains unknown. In the present study, we investigated the role of aldose reductase inhibitor epalrestat and its interaction with Kvb1 in the heart. Based on our findings, we identified that epalrestat an aldose reductase inhibitor prolongs the cardiac action potential. However, deletion of Kvb1.1 from the heart fails to invoke further prolongation observed in the wildtype hearts suggesting that binding of epalrestat to Kvb1 is likely causing the electrical modulation in the heart. Further, the sequence alignments and in silico binding demonstrate that epalrestat can interact with Kvb subunits arginine, a key amino acid, in binding NADPH to the active site as well as lysine which form the pyridine nucleotide binding pocket conserved in all Kvb proteins. This novel interaction likely interferes with the ability of NADPH to bind and interact with the Kvb subunit and modulate Kvb-mediated Kv channel gating.
Conclusions
This is the first study demonstrating the physiological role of Kvb1.1 and its interactions with corticosteroids to modulate cardiac action potential in the heart. The AR inhibitor epalrestat also shows in silico binding to Kvb subunit and modulates cardiac action potential ex vivo. Therefore, the present study provides new pharmacological information in terms of action potential modulation by Kvb subunit by corticosteroids or epalrestat. 
